Member Info for Bladderman

...AIM is the a**hole end of investing but that is not an excuse for their conduct.

How it was pumped for big holders (many Twitter mob included) to unload into news and volume at 15-18p. Then an orchestrated fall leaving PIs impaled. So many powerful stock fiddlers it's hard to judge these markets and investments. GLA

Surprised by the whole number off loading today which cut down the rise.

For a share to go up...

Postman..PAT

All the best..

Sad fall from yesterday. I almost bought at 2p/2.2p yesterday but was distracted. Has returned to a similar SP. A £1.5M MCap seems a bit silly but AIM is what it is. GLA

£2.4M MCap....jeez

So dont take it personally

Exposure and profile. It's a pioneering event

IMO this could build up to 9p+ in time for Liam's performance. That 12M short will be starting to sweat now..

Shake and vac. Full Ask being paid again 6p...

The fear of big pharma going phase III is the cost and risk. There is no risk now with Traumakine. The risk is removed!!

The beauty is though Cynoman is that Traumakine works in approximately 30% of humans with low toxicity. That is really significant as is really difficult to tick those boxes and the regulatory body kniws this. The future for FARN is now very very bright indeed!!

It's a silly and manipulated price. Once that stops it's game on. Also Clevegen and Yoda trial. Silly

Big..the medical fraternity are crying out for an effective ARDS therapeutic and this can potentially treat 30% of caucasion suffers. Wheels will turn quickly on this because of the un met need. Not worth 800p now but worth a hell of a lot more than 70 pence

Not sure about the sells at low 70s. This is being manipulated. JV or buy out which is a real possibility and this will be worth multiples of current price. He said the partners in discussion/coms were only updated yesterday uopn RNS release. Bet they're excitment about the development as it is very effective after all - even with steroids in a sub population. Boom

Agreed fast tracked in Jan 2019. There is a patient demand as no other non toxic compound with 'extremely' good efficacy in human sub population - juat steroid treatment which is very non specific and as the CEO stated has no reported quantitative benefit. ARDS suffers and need this and doctors will want to prescribe this unmet need. It could be the holy grail for 30% of caucasian suffers which is a very large market.

They have war chest money and could easily throw £50M at it if it could generate £200M for them per annum until 2040!!! A 20 year patent on an efficacious ARDS therapeutic is attractive to any mid tier to monster pharma with that sort of profit stream. Think big guys!!

JV with head honcho type like GSK or a 5 billion company like UCB based in the UK and Begium for example. Yum yum yum